Stakeholder Discussions on: Innovation, availability and affordability of medical products. Can we achieve it all?
On 1 February 2018, we at the Swiss Federal Institute of Intellectual Property held discussions on innovation, availability and affordability of medical products with a variety of selected stakeholders. The panelists had discussions on how innovation can address various types of diseases and on what is needed to make sure, innovation will not only be available but also affordable for patients. For more information, please go to our landing page.
The news service platform IP-Watch announced to publish a series of articles on ideas discussed at the event.:
- "Medicines Innovation and Access: Swiss Stimulate New Thinking". (06.02.2018)
- “Do We Need A Global Body To Set Priorities For Diseases And Research?" (14.02.2018)
This article not only discusses potential solutions regarding anti-microbial resistance and pandemic preparedness. It also highlights the role of the IPI as organiser of the event and mentions Albert Einstein as an IPI alumni.
Panellist Margaret Kyle – Ph.D MIT and economics professor at the Écoles des mines ParisTech - for instance said, we have much more information about a medical product at the time of the market launch than at the time of the patent application.
We wish you an enjoyable read.
SMEs used the lockdown period to develop new ideas – an insight into an initiative of the IPI during the coronavirus crisis
08.06.2020 | Patents
More support for innovative SMEs and start-ups – assisted patent searches at a reduced fee until the end of 2020
Better international protection for Swiss geographical indications
The IPI is actively participating in the WIPO dialogue on intellectual property and artificial intelligence
08.11.2019 | Event
Symposium on Creative Approaches to Improving Access to Medicines Globally
Roundtable on the protection of computer-implemented inventions